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ABSTRACT
Background Metastatic breast cancer is a leading cause 
of cancer- related death in women worldwide. Infusion of 
natural killer (NK) cells is an emerging immunotherapy 
for such malignant tumors, although elimination of the 
immunosuppressive tumor environment is required to 
improve its efficacy. The effects of this “metastatic” tumor 
environment on NK cells, however, remain largely unknown. 
Previous studies, including our own, have demonstrated that 
metastasis- associated macrophages (MAMs) are one of the 
most abundant immune cell types in the metastatic tumor 
niche in mouse models of metastatic breast cancer. We thus 
investigated the effects of MAMs on antitumor functions of 
NK cells in the metastatic tumor microenvironment.
Methods MAMs were isolated from the tumor- bearing 
lung of C57BL/6 mice intravenously injected with E0771- LG 
mouse mammary tumor cells. The effects of MAMs on NK 
cell cytotoxicity towards E0771- LG cells were evaluated 
in vitro by real- time fluorescence microscopy. The effects 
of MAM depletion on NK cell activation, maturation, and 
accumulation in the metastatic lung were evaluated by flow 
cytometry (CD69, CD11b, CD27) and in situ hybridization 
(Ncr1) using colony- stimulating factor 1 (CSF-1) receptor 
conditional knockout (Csf1r- cKO) mice. Finally, metastatic 
tumor loads in the chest region of mice were determined by 
bioluminescence imaging in order to evaluate the effect of 
MAM depletion on therapeutic efficacy of endogenous and 
adoptively transferred NK cells in suppressing metastatic 
tumor growth.
Results MAMs isolated from the metastatic lung 
suppressed NK cell- induced tumor cell apoptosis in 
vitro via membrane- bound transforming growth factor β 
(TGF-β) dependent mechanisms. In the tumor- challenged 
mice, depletion of MAMs increased the percentage of 
activated (CD69+) and mature (CD11b+CD27–) NK cells 
and the number of Ncr1+ NK cells as well as NK cell- 
mediated tumor rejection in the metastatic site. Moreover, 
MAM depletion or TGF-β receptor antagonist treatment 
significantly enhanced the therapeutic efficacy of NK cell 
infusion in suppressing early metastatic tumor outgrowth.
Conclusion This study demonstrates that MAMs are a 
main negative regulator of NK cell function within the 
metastatic tumor niche, and MAM targeting is an attractive 
strategy to improve NK cell- based immunotherapy for 
metastatic breast cancer.
INTRODUCTION
Metastatic breast cancer is largely refrac-
tory to current therapies and thus the most 
common cause of cancer- related death in 
women worldwide.1 Since up to 10% of 
patients with breast cancer already have meta-
static tumors at diagnosis,2 novel therapies 
that suppress metastatic tumor outgrowth are 
needed to improve patients’ survival. Given 
the recent success with checkpoint inhibitors 
that enhance CD8+ T cell- mediated tumor 
elimination, immunotherapy is now consid-
ered one of the most promising strategies 
to treat metastatic tumors.3 However, most 
advanced breast cancers downregulate major 
histocompatibility complex class- I (MHC- I) 
that is essential for effective killing by CD8+ 
T cells,4 and only a minority (1/25) of meta-
static patients with breast cancer respond to 
checkpoint inhibitors.5 Adoptive transfer 
of natural killer (NK) cells is proposed as a 
novel immunotherapy to treat such types of 
cancer, since NK cells do not require MHC- I 
dependent priming to exert their cytotox-
icity.6 Instead, loss of MHC- I on target cells 
drives activation of NK cells.7 The infusion 
of ex vivo expanded NK cells has been eval-
uated in a clinical context and found to 
exert modest clinical responses without any 
side effects in patients with metastatic breast 
cancer.6 8 Conversely, it has been suggested 
that the cytotoxicity of NK cells is restricted 
within the tumor microenvironment and 
elimination of this immune suppressive envi-
ronment is needed to improve efficacy of NK 
cell infusion therapy.8 9
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In this study, we identified that NK cell cytotoxicity 
is suppressed by metastasis- associated macrophages 
(MAMs) via transforming growth factor β (TGF-β) and 
that depletion of MAMs or blockade of TGF-β signaling 
enhances efficacy of infused NK cells in suppressing early 
metastatic tumor outgrowth (online supplemental file 1).
MATERIALS AND METHODS
Mice
C57BL/6JCrl mice were obtained from Charles River 
and housed in a specific pathogen free room. Colony- 
stimulating factor 1 (CSF-1) receptor conditional 
knockout (Csf1r- cKO) mice (ie, rtTA:tetO- Cre:Csf1rF/F) 
on a C57BL/6 background were obtained by crossing 
the B6.Cg-Csf1rtm1Jwp/J (ie, Csf1rF/F) mice with ROSA- rtTA 
and tetO- Cre mice (The Jackson Laboratory).10 11 In some 
experiments, C57BL/6JCrl mice (4- week- old females) 
were irradiated with 9 Gy γ-rays and transplanted with 
4×106 bone marrow cells isolated from Csf1r- cKO mice. 
The bone marrow transplanted mice (Csf1r- cKO:BMT) 
were used for experiments 6 weeks later.
Cell culture
E0771- LG cells, a highly metastatic derivative of E0771 
mouse mammary adenocarcinoma cells that originated 
from a medullary cancer in C57BL/6 mice,12 were manip-
ulated to express firefly luciferase (E0771- LG:Fluc) and a 
nuclear localized red fluorescent protein mKate2 (E0771- 
LG:Fluc_NLR) as previously described.11 13 These tumor 
cells were cultured in Dulbecco's Modified Eagle Medium 
(DMEM) including 10% fetal bovine serum (FBS), 100 U/
mL penicillin, and 100 μg/mL streptomycin at 37°C, 5% 
CO2. Bone marrow- derived macrophages (BMMs) were 
prepared from the femur and tibia of C57BL/6JCrl 
mice,14 and were cultured in αMEM (Gibco) including 
10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 
and recombinant murine 20 ng/mL macrophage colony- 
stimulating factor (M- CSF; PeproTech) or 25 ng/mL 
granulocyte- macrophage colony- stimulating factor (GM- 
CSF; PeproTech). NK cells were isolated from the spleen 
of C57BL/6JCrl mice (female, 8 weeks of age) using 
EasySep Mouse NK Cell Isolation Kit (StemCell Technol-
ogies) and cultured in αMEM including 20% FBS, 2 mM 
L- glutamine, 1% non- essential amino acid, 1 mM sodium 
pyruvate, 50 nM 2- mercaptoethanol, 100 U/mL penicillin, 
100 μg/mL streptomycin (all from Gibco), and 1000 U/
mL murine interleukin (IL)-2 (PeproTech).
Mouse model of metastatic breast cancer
1×106 of E0771- LG:Fluc cells were injected into the 
tail vein of syngeneic C57BL/6JCrl or Csf1r- cKO mice 
(7–12- week- old females). To detect tumor cells in the 
chest region, mice received intra- peritoneal injection of 
D- luciferin (1.5 mg/20 g mouse, Gold Biotechnologies) 
and were imaged by Photon IMAGER Optima (Biospace 
Lab) every 3–4 days. The metastatic tumor loads indicated 
by photon count (photon/s/cm2/sr) were quantified by 
M3 Vision Software (Biospace Lab). At day 4 after tumor 
injection, animals with micro- metastases (suggested by 
photon count 2.5×102–1.0×103) were randomly divided 
into groups and received following treatments. To deplete 
macrophages, Csf1r- cKO mice were given doxycycline in 
the drinking water (Sigma, 2 mg/mL in 5% sucrose water) 
from day 4 after tumor injection until the end of the 
experiment. To deplete NK cells, anti- NK1.1 neutralizing 
antibody (BioXCell, 200 mg/20 g mouse) was injected 
into the peritoneum on days 4 and 7 after tumor injec-
tion. In some experiments, 1×106 NK cells were injected 
via the tail vein on day 7 and day 10 after tumor injection. 
NK cells were preactivated with 1000 U/mL IL-2 (Pepro-
Tech) for 24 hours before injection as described earlier. 
To block TGF-β signaling, a selective TGF-β receptor 
antagonist LY346947 (Seleckchem, 0.2 mg/20 g mouse) 
was injected into the peritoneum every 2 days from day 4 
after tumor injection.
Flow cytometry and sorting
Lungs were perfused with phosphate- buffered saline 
(PBS) and isolated from mice at day 14 after tumor injec-
tion. Single- cell suspensions were prepared via enzymatic 
digestion using the Lung Dissociation Kit (Miltenyi) 
and subsequent filtration through a 40 μm cell strainer 
(Falcon). Cells were treated with red blood cell lysis 
buffer (Biolegend) and resuspended in PBS including 
2% bovine serum albumin (BSA; Sigma). 1×106 cells were 
incubated with 1 μL of anti- mouse CD16/CD32 antibody 
(Fc Block, BD Bioscience) for at least 15 min on ice, and 
stained for 60 min with antibodies to the following anti-
gens; CD45 (30- F11), CD11b (M1/70), CD11c (N418), 
Ly6C (HK1.4), Ly6G (1A8), CD3 (17A2), NK1.1 (PK136), 
CD4 (GK1.5), CD8 (53–6.7), CD19 (6D5), H2- Kb (AF6-
88.5), H2- Db (KH95), LAP/TGF-β1 (TW7- 16B4), CD69 
(H1.2F3), CD27 (LG.3A10), CD49a (HMa1), CD49b 
(DX5), NKp46 (29A1.4), DNAM1 (10E5), NKG2D 
(C7), Ly49A (YE1/48.10.6), Ly49C (14B11), NKG2A 
(16A11) from Biolegend, H2- Qa1 (6A8.6F10.1A6) from 
Novus, and F4/80 (Cl:A3-1) from Bio- Rad. Cells were 
resuspended in PBS including 2% BSA and 3 μM DAPI 
(BioLegend) before analysis. To detect FoxP3, cells were 
permeabilized by Fixation Permeabilization Reagent 
(eBioscience) for 30 min at room temperature, blocked 
with 2% normal rat serum, and stained with anti- FoxP3 
antibody (FJK- 16s, eBioscience) for 30 min at room 
temperature. Flow cytometry was performed using the 
LSRII cytometer (BD Biosciences) and analyzed using 
Flowjo software (TreeStar). For some experiments MAMs, 
monocytic myeloid- derived suppressor cells (M- MDSCs), 
and resident macrophages (RMACs) were sorted from 
the lung of tumor- injected mice using FACS Aria II (BD 
Bioscences).
In vitro NK cell cytotoxicity assay
1×103 target cells (E0771- LG:Fluc_NLR cells), 4×103 
effector cells (splenic NK cells), and/or 3×103 suppressor 
cells (macrophages or MDSCs isolated from the lung 
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containing E0771- LG metastatic tumors) were seeded 
into 96- well plates (Nunc) precoated with basement 
membrane extract (Geltrex, Gibco). These cells were 
cocultured in αMEM including 10% FBS, 1% penicillin/
streptomycin, 1000 U/mL IL-2 (PeproTech), 20 ng/mL 
M- CSF (PeproTech), and 2.5 μM fluorogenic caspase-3 
substrate (NucView 488, Biotium) at 37°C, 5% CO2, 
and imaged by IncuCyte Zoom Live- Cell Analysis System 
(Sartorius) at 10× magnification for up to 48–72 hours. 
The numbers of apoptotic tumor cells (nuclei showing 
large areas of overlapping red/green fluorescence) were 
counted using the IncuCyte Zoom software (Sartorius) 
as previously described.13 In some experiments, the 
following antibodies (25 μg/mL) were added in culture: 
anti- Ly49A (YE1/48.10.6), anti- H2- Kb (AF6-88.5), anti- 
TGF-β (19D8) from BioLegend, H2- Db (28-14-8), and 
Ly49C/I (5E6) from BD Biosciences.
Histological analysis
Perfused lungs in tumor- injected mice were isolated at 
day 10 after tumor injection and fixed with 10% neutral 
buffered formalin overnight. The lungs were embedded 
in paraffin and cut into 4 μm sections for immunohisto-
chemistry (IHC) or in situ hybridization (ISH). For IHC, 
sections were deparaffinised, pretreated with hydrogen 
peroxide and incubated with Enzyme 1 (Leica, UK) for 
10 min at 37°C to retrieve antigen. The sections were then 
stained using Rat ImmPRESS kit (Vector Labs) and Bond 
Intense R Detection System (Leica) with F4/80 antibody 
(1/200, polyclonal, Abcam). For ISH, sections were 
deparaffinised and pretreated with hydrogen peroxide, 
followed by hybridization with probes (NKp46; Mm- NCR1 
or Control: Mm- UBC, Advanced Cell Diagnostics). Posi-
tive signals for Ncr1 (mRNA coding NKp46) were detected 
using RNAscope 2.5 LS- Brown Reagent Kit (Advanced 
Cell Diagnostics). Nuclei were counter stained by hema-
toxylin. Both staining processes were carried out using 
the Bond Rx Automated Stainer (Leica). Stained sections 
were dehydrated through graded alcohols and xylene and 
covered by a glass cover with DPX Mounting Media (Cell-
Path). The stained slides were scanned by Axioscan.Z1 
(Carl Zeiss) using a 40×0.95 NA Plan- Apochromat objec-
tive lens and analyzed by Tissue Studio V.4.4.2 software 
(Definiens). Briefly, cell nuclei showing blue color over 
the threshold were masked, and the region with dense 
nuclei localization was outlined as the tumor area. The 
size of each tumor area and total non- tumor area in the 
field were determined, and the number of brown spots 
that suggest Ncr1 or F4/80 expressing cells was counted 
in each area.
Statistical analyses
All samples were collected independently and analyzed 
from at least two independent experiments. Data were 
expressed as mean±SEM Significance was tested using the 
Student’s t test unless it is specified. P<0.05 was consid-
ered significant. Statistical analyzes were carried out using 
GraphPad Prism V.6.
RESULTS
MAMs suppress NK cell induced tumor cell apoptosis in vitro
Using mouse models of metastatic breast cancer, we 
demonstrated that distinct myeloid cell populations 
termed MAMs and M- MDSCs in the metastatic lung 
suppress CD8+ T cell cytotoxicity in vitro.15 We thus 
hypothesized that MAMs and/or M- MDSCs also play key 
roles in suppression of NK cells in the metastatic tumor 
microenvironment.
To investigate this hypothesis, we used an experimental 
metastasis model where intravenously injected mouse 
mammary tumor cells (E0771- LG) reproducibly develop 
metastatic tumors in the lung of syngeneic C57BL/6 
mice.11 15 In this model, numbers of M- MDSCs and 
MAMs, but not lung RMACs, were significantly increased 
in the lung containing metastatic tumors established 
by E0771- LG:Fluc cells (online supplemental figure 1 
and figure 1A).15 Although regulatory T (Treg) cells are 
reported to inhibit NK cell- mediated tumor rejection in 
a mouse model of lung cancer,16 their contribution in 
our model should be minor as the number of Treg cells 
was reduced rather than increased in the metastatic lung 
compared with the normal lung (figure 1A).
We then investigated effects of MAMs and M- MDSCs on 
NK cell cytotoxicity against tumor cells. To this end, we 
established an in vitro assay where tumor cells expressing 
a red fluorescent protein (E0771- LG:Fluc_NLR) were 
cultured with normal splenic NK cells and the number 
of apoptotic tumor cells indicated by green fluores-
cence from a fluorogenic caspase-3 substrate was deter-
mined (figure 1B). In this assay, the apoptotic fraction 
(ie, the ratio of apoptotic (red/green double positive) 
tumor cells to total (red) tumor cells) was significantly 
elevated in accordance with increased tumor to NK cell 
(T:N) ratio (figure 1C) and reached the maximum at a 
1:4 ratio by 36 hours of coculture (figure 1D). We thus 
cultured E0771- LG:Fluc_NLR and NK cells with MAMs or 
M- MDSCs at a 1:4:3 ratio (tumor:NK:myeloid cell) for 24 
hours, and found that NK cell- induced tumor cell apop-
tosis (T+N) was significantly reduced in the presence of 
MAMs, but not M- MDSCs (figure 1E). RMACs isolated 
from the normal lung also did not affect cytotoxicity of 
NK cells. These results demonstrate that MAMs rather 
than M- MDSCs or RMACs play pivotal roles in NK cell 
suppression in the metastatic site.
Macrophages suppress NK cell cytotoxicity in vitro by TGF-β 
rather than MHC-I molecules
To further show that a distinct macrophage population 
is responsible for NK cell suppression, we investigated 
bone marrow- derived macrophages (BMMs) cultured 
with M- CSF (also known as CSF-1) or GM- CSF, called 
M- BMMs and GM- BMMs, respectively (online supple-
mental figure 2A). It is reported that the gene expression 
profile of GM- BMMs is closer to that of macrophages 
than to dendritic cells and is clearly distinct from that of 
M- BMMs.17 18 The phenotype of GM- BMMs (F4/80+CD-
11bLowCD11cHigh) is also distinguishable from that of 
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M- BMMs (F4/80+CD11bHigh CD11cLow) (online supple-
mental figure 2), which represent RMACs and MAMs 
in the metastatic lung, respectively.19 NK cell- mediated 
tumor cell apoptosis was significantly reduced when 
M- BMMs were added into the coculture at either 1:4:1 or 
1:4:3 ratios (tumor cell:NK cell:myeloid cell). In contrast, 
GM- BMMs did not change the NK cell- induced tumor cell 
apoptosis (figure 2A), suggesting that NK cell suppres-
sion is a specific feature of certain types of macrophages 
such as MAMs and their mimetic M- BMMs, rather than 
a common characteristic of all macrophage populations.
We further performed the NK cell cytotoxicity assay in 
“non- contact” conditions where M- BMMs were placed 
in a Transwell chamber to physically separate them 
from tumor and NK cells, and found that M- BMMs 
under this condition did not reduce the apoptotic frac-
tion of tumor cells cultured with NK cells (figure 2B). 
Therefore, macrophages require cell- to- cell contact 
to inhibit NK cell cytotoxicity. Since MHC- I molecules 
are cell surface ligands that can inhibit NK cell func-
tions through their cognate receptors on NK cells,20 we 
investigated expression of MHC- I molecules detectable 
by flow cytometry in C57BL/6 mice (ie, H2- Kb, H2- Db, 
and H2- Qa1) in M- BMMs and GM- BMMs. The surface 
expression of H2- Kb and H2- Db was significantly higher 
in M- BMMs than GM- BMMs whereas H2- Qa1 expression 
was not significantly different between the BMM subtypes 
(figure 2C). We thus hypothesized that M- BMMs might 
suppress NK cell cytotoxicity via H2- Kb and/or H2- Db. 
However, blocking antibodies against H2- Kb, H- 2Db, or 
their receptors Ly49C/I did not rescue the suppression 
of NK cell cytotoxicity caused by M- BMMs (figure 2D). 
Blockade of another inhibitory receptor, Ly49A, also 
did not reverse the BMM- mediated NK cell suppression 
(figure 2D). These results suggest that MHC- I mole-
cules play minor roles in macrophage- mediated NK cell 
suppression in the in vitro models.
We then investigated the involvement of membrane- 
bound TGF-β (mb- TGF-β) in the in vitro macrophage 
models, since Treg cells and MDSCs are reported to 
suppress NK cell functions in a cell contact- dependent 
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Figure 1 MAMs suppress cytotoxicity of natural killer (NK) cells in vitro. (A) Number of cells per milligram of lung tissue 
in untreated (normal; N) or tumor- injected (T) C57BL/6 mice at day 14 after tumor injection (n=3 in each group from two 
experiments). (B) Representative images from seven experiments showing cells in the red channel, green channel, and phase 
contrast merged with red and green channels. E0771- LG:NLR tumor cells were cultured with splenic NK cells at 1:4 of tumor:NK 
ratio in the presence of caspase-3 substrate for 24 hours. The right panel shows the same field under the red/green overlap 
mask where apoptotic tumor cells (large green fluorescent nuclei colocalized with red fluorescence, orange arrow heads) were 
distinguished from apoptotic NK cells (white arrow heads) and non- apoptotic tumor cells (blue arrowheads). Scale bar shows 
100 µm. (C) Apoptotic fraction (ratio of apoptotic cells in total cells) of tumor cells (T) cultured with NK cells (N) at different T:N 
ratios for 24 hours (n=5 in each condition from five experiments). Data are normalized to tumor cell monoculture (T:N=1:0). 
(D) Apoptotic fraction of tumor cells cultured with NK cells at 1:4 of T:N ratio (T+N) or on their own (T only) for up to 54 hours 
(n=10 in each condition from ten experiments). Asterisk shows statistical significance compared with T only. (E) Apoptotic 
fraction of tumor cells cultured with NK cells (T+N) or with NK cells and myeloid cells (T+N+MDSC; T+N+MAM; T+N+RMAC) 
for 24 hours (n=8 in each condition from seven experiments). Tumor, NK, and myeloid cells were cocultured at 1:4:3 ratio. Data 
are normalized to T+N. All data show mean±SEM for all analyses: *p<0.05; **p<0.01; ***p<0.001; ns, not significant. MAM, 
metastasis- associated macrophage; M- MDSC, monocytic- myeloid derived suppressor cells; RMAC, resident macrophage; Treg, 
regulatory T cell.
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expression was significantly higher in NK suppressive 
M- BMMs compared with non- suppressive GM- BMMs 
(figure 2E,F). Moreover, in metastatic tumor bearing 
lungs, MAMs expressed significantly higher mb- TGF-β 
than neutrophils, T cells (CD4 and CD8) and NK cells, 
whereas MDSCs and RMACs also expressed high levels 
of mb- TGF-β (figure 2 and online supplemental figure 
3). We thus investigated the effects of an anti- TGF-β 
blocking antibody on macrophage- mediated NK cell 
suppression. In the presence of control IgG, M- BMMs 
and MAMs reduced NK cell- induced tumor cell apoptosis 
(figure 2H). However, this macrophage- mediated NK 
suppression was significantly inhibited by the anti- 
TGF-β antibody treatment (figure 2H), which suggests 
that macrophages suppress NK cell cytotoxicity through 
expression of mb- TGF-β rather than MHC- I molecules in 
our model.
MAMs regulate activation, maturation, and accumulation of 
NK cells in the metastatic niche
To investigate the effects of MAMs on NK cell phenotype 
and functions in the metastatic tumor microenvironment, 
Figure 2 Macrophages suppress NK cell cytotoxicity via membrane bound TGF-β rather than major histocompatibility 
complex class- I (MHC- I) molecules. (A) Apoptotic fraction of tumor cells cultured with NK cells at 1:4 of T:N ratio for 24 hours in 
the absence (T+N) or presence of bone marrow- derived macrophages (BMMs) cultured with M- CSF (T+N+M- BMM) or GM- CSF 
(T+N+GM- BMM) (n=8 in each condition from five experiments). Tumor to BMM ratio (T:BMM) is shown at the bottom. Data are 
normalized to T+N. (B) Apoptotic fraction of tumor cells cultured with NK cells in the absence (T+N) or presence (T+N+M- BMM) 
of M- BMMs under contact or non- contact conditions at 1:4:3 of T:N:BMM ratio for 24 hours (n=7 in each condition from four 
experiments). Data are normalized to T+N. (C) Geometric mean fluorescence intensity of H2- Kb, H2- Db, and H2- Qa1 on M- 
BMMs and GM- BMMs (n=5 from three experiments). (D) Apoptotic fraction of tumor cells cultured with NK cells (T+N) or with 
NK cells and M- BMMs (T+N+M- BMM). Cells were cultured with antibodies (Abs) against MHC- I molecules or their receptors 
denoted underneath (n=5 in each condition from five experiments). Data are normalized to T+N. P values were calculated by 
Kruskal- Wallis test. (E) Representative histogram showing membrane- bound TGF-β (mb- TGF-β) on BMMs. Dotted lines show 
control isotype matched IgG for each cell type (n=4 from four experiments). (F and G) Geometric mean fluorescence intensity 
of mb- TGF-β on BMMs (F; n=4 from four experiments) and major immune cells within the tumor- bearing lung at day 14 (G; 
n=6 from two experiments). Asterisk in G shows statistical significance compared with MAM. (H) Apoptotic fraction of tumor 
cells cultured with NK cells (T+N) or with NK cells and macrophages (T+N+M- BMM; T+N+MAM) in the presence of anti- TGF-β 
antibody or isotype matched IgG (n=5 in each condition from four independent experiments). Data are normalized to T+N 
(dotted gray line). P values were calculated by Kruskal- Wallis test. All data show mean±SEM for all analyzes: *p<0.05; **p<0.01; 
***p<0.001; ns, not significant. MAM, metastasis- associated macrophage; MFI, mean fluorescence intensity; M- MDSC, 
monocytic- myeloid derived suppressor cells; NK, natural killer; RMAC, resident macrophage; TGF-β, transforming growth factor 
β.
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we used CSF-1 receptor conditional knockout (Csf1r- cKO) 
mice in which floxed CSF-1 receptor genes (Csf1rF/F) are 
deleted and thereby certain macrophage populations 
are ablated on doxycycline treatment.11 We injected 
E0771- LG tumor cells into the tail vein of Csf1r- cKO mice 
and treated with either doxycycline or vehicle from day 4 
after tumor cell injection, a time point when tumor cells 
develop micro- metastases within the lung (figure 3A).15 
As we have reported previously,15 doxycycline treatment 
significantly reduced the accumulation of MAMs, but not 
M- MDSCs or RMACs in the metastatic lungs of Csf1r- cKO 
mice (figure 3B).
Using this model, we first investigated the effects of 
MAM depletion on the expression of CD69, an NK cell 
activation marker. In vehicle treated Csf1r- cKO mice, 
the percentage of CD69+ NK cells was significantly 
lower in tumor- bearing lungs (43%±4%) compared 
with blood (62%±2%), suggesting the existence of an 
immune suppressive environment at the metastatic site 
(figure 3C). In contrast, the ratio of CD69 expressing 
Figure 3 MAM depletion increases NK cell activation, maturation, and accumulation of NK cells within tumor bearing lungs. 
(A) A scheme of MAM depletion. Csf1r- cKO mice were intravenously injected with E0771- LG:Fluc cells and treated with 
doxycycline (Dox) from day 4 after tumor injection. The tumor- bearing lungs were isolated on day 14. (B) Percentage of MAMs, 
M- MDSCs, and RMACs in CD45+ cells in the metastatic lung of Csf1r- cKO mice treated with Dox or vehicle (n=6 in each group 
from two experiments). (C) Percentage of CD69+ cells in NK cells in the blood and lung with metastatic tumors in Csf1r- cKO 
mice treated with Dox or vehicle (n=9 in each group from two experiments. (D) Geometric mean fluorescence intensity (gMFI) of 
NK cell activating receptors (NKp46, DNAM1, NKG2D) and inhibitory receptors (Ly49A, Ly49C, NKG2A) on NK cells in the lung 
with metastatic tumors in Csf1r- cKO mice treated with Dox or vehicle (n=6 in each group from three experiments). (E) Frequency 
of NK cell subsets defined by CD11b and CD27 expression (denoted below) in the lung with metastatic tumors in Csf1r- cKO 
mice treated with Dox or vehicle (n=6 in each group from two experiments). All data show mean±SEM for all analyzes: *p<0.05; 
**p<0.01; ***p<0.001; ns, not significant. (F–I) Expression of F4/80 and NKp46 (Ncr1) in the lung with metastatic tumors in 
Csf1r- cKO mice treated with vehicle or Dox. (F and H) Representative stained images of tumor area (surrounded by dotted line) 
and non- tumor area. Scale bar shows 100 µm. (G and I) Number of F4/80+ or NKp46+ cells per mm2 of tumor area and non- 
tumor area (n=6 mice in each group. Total 111 and 152 tumors in vehicle and Dox were analyzed, respectively. All data show 
mean±SEM for all analyzes: *p<0.05; ***p<0.001; ns, not significant. MAM, metastasis- associated macrophage; M- MDSC, 
monocytic- myeloid derived suppressor cells; NK, natural killer; RMAC, resident macrophage.
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NK cells in the tumor- bearing lung was significantly 
increased in doxycycline treated mice compared with 
vehicle treated mice (figure 3C). It is reported that CD69 
expression is increased on activation of NK cells and high 
CD69 expression correlates with high cytotoxic activity of 
circulating NK cells.23 24 Although tissue resident NK cells 
(characterized by CD49a expression) can also “constantly” 
express CD69,25 the number of CD49a+ NK cells was very 
low in the lung25 26 and was not changed by doxycycline 
treatment (online supplemental figure 4). Therefore, the 
increase in CD69+ NK cells by MAM depletion is likely to 
be caused by enhanced activation of tumor- infiltrating NK 
cells rather than accumulation of tissue resident NK cells 
within the metastatic lung. Together with data from our 
in vitro assays, these results indicate that MAMs suppress 
NK cell activation within the metastatic tumor niche.
Using the same model, we further investigated other 
potential mechanisms by which MAMs might inhibit NK 
cell functions in vivo. We first investigated the effects of 
MAM depletion on the expression of NK cell activating 
receptors such as NKp46, NKG2D, and DNAM-1, as 
signaling through these receptors promotes the cytolytic 
ability of NK cells20 27 and other suppressor cells such 
as Treg cells can induce anergy of NK cells by downreg-
ulating NKG2D expression on NK cells.21 In the meta-
static lung of vehicle- treated Csf1r- cKO mice, NK cells 
expressed detectable levels of NKp46, NKG2D, and 
DNAM-1. However, doxycycline treatment did not alter 
their expression (figure 3D). Although NK cells in the 
metastatic lung expressed inhibitory receptors including 
Ly49A, Ly49C/I, and NKG2A that negatively regulate NK 
cell cytotoxicity,20 27 their expression was also not changed 
by MAM depletion (figure 3D). It is therefore unlikely 
that MAMs inhibit cytotoxicity of NK cells by modulating 
the expression of NK cell regulatory receptors.
We next investigated the effects of MAM depletion 
on the maturation of NK cells defined by differential 
surface expression of CD11b and CD27, as mouse NK 
cells acquire effector functions through four consecutive 
maturation stages; CD11b–CD27–→CD11b–CD27+→CD-
11b+CD27+→CD11b+CD27–.28 In the metastatic lung 
of doxycycline treated mice, the percentage of “imma-
ture” NK cells (CD11b–CD27– and CD11b–CD27+) was 
significantly reduced and the ratio of the most mature 
NK subset (CD11b+CD27–) was concomitantly increased 
(figure 3E). These results suggest that MAMs prevent 
maturation of NK cells at the metastatic site.
We further investigated the effects of MAM depletion on 
NK cell infiltration into metastatic tumors. To this end, we 
detected F4/80 positive macrophages and NKp46 (Ncr1) 
expressing NK cells in the metastatic lung by IHC and 
in situ RNA hybridization, respectively. Consistent with 
our previous data, the number of F4/80+ macrophages 
in the tumor area (considered MAMs) was reduced in 
Csf1r- cKO mice treated with doxycycline compared with 
those treated with vehicle, whereas the number of macro-
phages in the lung parenchyma was not changed between 
the groups (figure 3F,G). In contrast, the number of NK 
cells within the tumor area was significantly higher in 
doxycycline treated mice compared with vehicle treated 
animals (figure 3H,I). The number of NK cells in the 
lung parenchyma (non- tumor area) was also increased by 
doxycycline treatment in tumor- bearing Csf1r- cKO mice. 
Collectively, these results suggest that MAMs suppress 
activation, maturation, and accumulation of NK cells in 
the metastatic tumor microenvironment.
MAM targeting enhances efficacy of NK cells in suppressing 
metastatic tumor outgrowth
We thus hypothesized that depletion of MAMs would 
suppress metastatic tumor outgrowth by promoting NK 
cell functions. To investigate this hypothesis, tumor- 
injected Csf1r- cKO mice were treated with doxycycline 
and injected with anti- NK1.1 antibody, which depletes 
MAMs (figure 3B) and NK cells29 in the metastatic lung, 
respectively. As a MAM- intact control, syngeneic C57BL/6 
mice were given the same treatments. In order to trace 
the metastatic tumor growth in the lung, E0771- LG 
cells expressing firefly luciferase (E0771- LG:Fluc) were 
injected into the tail vein of mice. We have reported that 
intravenously injected E0771- LG:Fluc cells reproducibly 
extravasate into the lung by day 2, develop into small 
metastatic foci by day 7, and grow into macro- metastatic 
lesions by day 14.11 15 We thus started doxycycline and/
or anti- NK1.1 antibody treatment from day 4 after tumor 
cell injection in order to investigate effects of the treat-
ments on the expansion of metastatic tumor cells after 
their seeding (figure 4A).
Upon treatment with doxycycline and control IgG, meta-
static tumor loads within the lung area were significantly 
reduced in Csf1r- cKO mice compared with C57BL/6 mice 
at day 7 after tumor injection (figure 4B,C). However, the 
reduction in metastatic tumor load seen in Csf1r- cKO 
mice was significantly reversed by depletion of NK cells 
(figure 4B,C). The average tumor load at day 10 in 
Csf1r- cKO mice treated with IgG was also lower than that 
of control C57BL/6 mice, although this was not statisti-
cally significant. These data suggest that MAM depletion 
suppresses the expansion of metastatic tumor cells by 
activating NK cells during the early phase of metastasis, 
whereas activation of intrinsic NK cells is not sufficient to 
block later metastatic tumor expansion.
We then investigated whether adoptive NK cell transfer 
can inhibit metastatic tumor outgrowth in the presence 
or absence of MAMs. In order to restrict genetic alter-
ations to blood cells, we transferred bone marrow cells 
from Csf1r- cKO mice into lethally irradiated recipient 
C57BL/6 mice in this experiment (figure 5A). Consis-
tent with our previous results (figure 4), metastatic tumor 
growth in Csf1r- cKO:BMT mice treated with doxycycline 
was suppressed by day 7 after tumor injection whereas it 
was increased by day 10 (figure 5B,C). Importantly, adop-
tive transfer of NK cells significantly reduced the meta-
static tumor load at day 10 in doxycycline treated mice, 
but not in vehicle treated mice (figure 5B,C). Therefore, 
the depletion of MAMs not only enhances intrinsic NK 
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cell activity but also improves the efficacy of transferred 
NK cells, which can suppress metastatic tumor expansion.
To investigate the involvement of TGF-β in the MAM- 
mediated constraint of infused NK cell efficacy, tumor 
injected C57BL/6 or Csf1r- cKO mice were treated with 
the potent and selective TGF-β receptor antagonist 
(LY364947) and doxycycline from day 4 after tumor injec-
tion (figure 6A). This treatment by itself did not change 
metastatic tumor growth in C57BL/6 mice (figure 6B). 
We then adoptively transferred NK cells into a cohort of 
mice on days 7 and 10 and found that NK cell infusion 
in combination with LY364947 treatment significantly 
reduced metastatic tumor load at day 10 after tumor 
injection (figure 6C). In contrast, LY364947 treatment 
did not affect the efficacy of transferred NK cells in 
the macrophage- depleted Csf1r- cKO mice (figure 6D), 
which strongly suggests that MAMs suppress efficacy of 
infused NK cells in part through expression of TGF-β. In 
this model, NK cell injection with LY364947 treatment 
or macrophage depletion did not significantly suppress 
the late metastatic tumor growth from day 10 to day 14 
(figure 6C,D). Collectively, these data demonstrate that 
MAM targeting (eg, depletion of MAM or blockade of 
TGF-β signal transmission by MAMs) promotes NK cell 
cytotoxicity and thereby enhances efficacy of NK cell 
infusion in suppressing “early” metastatic tumor expan-
sion, whereas further improvement of NK cell efficacy 
is required to suppress ”late” stage of metastatic tumor 
growth.
DISCUSSION
NK cell infusion therapy has been identified as a novel 
immunotherapy to treat malignant tumors including 
metastatic breast cancer that are resistant to conven-
tional therapies. However, NK cells do not exhibit their 
full cytotoxic capacity in vivo compared with in vitro and 
are not effective in treating most solid tumors.30 Thus, 
identification and thereby blockade of immune suppres-
sive factors in the tumor microenvironment represents a 
key issue in order to design effective NK cell- based thera-
pies for solid tumors. However, the major component of 
the NK cell suppressive tumor microenvironment seems 
to be different between tumor types. For example, NK 
cell- mediated tumor rejection in the metastatic lung is 
suppressed by Treg cells in a mouse model of melanoma,
16 
whereas NK cell activation is suppressed by MDSCs 
rather than Treg cells in mouse models of liver and lung 
cancer.22 31 Therefore, a better understanding of target 
cell types characteristic for metastatic breast cancer is 
important to improve the therapeutic effects of NK cells 
on this lethal disease. Here we have shown, to our knowl-
edge for the first time, that MAMs are the main negative 
anti-NK1.1 Ab or IgG















































































Figure 4 Depletion of MAMs suppresses metastatic tumor expansion via natural killer (NK) cell- mediated mechanism. (A) A 
scheme of metastasis- associated macrophage and NK cell depletion. Csf1r- cKO mice or control C57BL/6 mice intravenously 
injected with E0771- LG:Fluc cells were treated with doxycycline (Dox) from day 4 to day 10 after tumor injection. The animals 
were also injected with anti- NK1.1 antibody (αNK) or control IgG into the peritoneum on days 4 and 7. (B and C) Representative 
bioluminescence images (B) and mean metastatic tumor loads (C) on days 4, 7, and 10 after tumor injection (n=5, C57BL/6:IgG; 
n=4, C57BL/6:αNK; n=6, Csf1r-cKO:IgG; n=6, Csf1r- cKO:αNK from two experiments). P values were calculated by Kruskal- 
Wallis test. All data show mean±SEM; *p<0.05; **p<0.01; ns, not significant.
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regulator of NK cells in the metastatic tumor niche estab-
lished in a mouse model of metastatic breast cancer.
In mouse models of breast cancer, MAMs are recruited 
to the tumor challenged lung and promote extravasa-
tion and survival of metastasizing tumor cells, which 
accelerates the establishment of lethal metastatic 
foci.19 32 Therefore, blockade of MAMs have been consid-
ered an important therapeutic strategy to prevent meta-
static tumor outgrowth.33 34 In this study, we have shown 
that depletion of MAMs can inhibit metastatic expansion 
of breast cancer cells not only by restricting pro- metastatic 
tumor cell functions but also by promoting NK cell medi-
ated antitumor immune reactions in the metastatic site. 
In contrast to MAMs, RMACs in the normal lung did not 
suppress NK cell cytotoxicity. Interestingly, we have found 
that BMMs cultured with GM- CSF also do not suppress NK 
cell- induced apoptosis of mammary tumor cells, whereas 
BMMs cultured with M- CSF do. Since CSF-1 signaling is 
essential for the differentiation and survival of MAMs 
but not RMACs in the metastatic lung,15 19 these data 
suggest that CSF-1 dependent macrophage populations 
including MAMs acquire NK cell suppressive functions 
and can be a therapeutic target to boost antitumor NK 
cell functions. In contrast, RMACs in the lung of normal 
mice are reported to promote the cytotoxicity of NK cells 
in vitro,35 suggesting that RMACs in the lung have poten-
tial to activate rather than suppress antitumor NK cell 
functions. In fact, RMACs in the tumor- challenged lung 
activate intrinsic NK cells and thereby restrict pulmonary 
metastasis formation on treatment with blocking anti-
bodies for CD39 in a mouse model of melanoma.36
We suggest here that one of the major mechanisms 
behind NK cell suppression by MAMs and M- BMMs is 
the expression of mb- TGF-β. Consistent with our results, 
bone marrow derived macrophages cultured with M- CSF 
in combination with IL-4 and IL-13 can inhibit NK cell 
expression of a degranulation marker CD107a in a TGF-β 
and contact- dependent manner.37 Although precise 
mechanisms by which mb- TGF-β suppress NK cells have 
not been identified yet, TGF-β is reported to reduce the 
expression of an NK- activating receptor NKG2D in NK 
cells, which is associated with impaired NK cell cytotox-
icity.38 Another study suggests that TGF-β promotes the 
conversion of NK cells (CD49a–CD49b+) into less cyto-
toxic type I innate lymphoid cells (CD49a+CD49b–), 
which can also inhibit NK cell- mediated immune surveil-
lance.39 However, it is unlikely that MAMs use these mech-
anisms in our model since depletion of MAMs did not 
change the expression of activating and inhibitory recep-
tors on NK cells or percentage of CD49a+CD49b– cells in 
the metastatic lung. Thus, further studies are needed to 
delineate how mb- TGF-β limits NK cell- mediated anti-
tumor immune reactions. Interestingly, mb- TGF-β was 
expressed also by M- MDSCs at comparable levels to MAMs, 
whereas M- MDSCs did not suppress NK cell cytotoxicity 
toward cancer cells in vitro. Since M- MDSCs can differen-
tiate into MAMs at the metastatic site,15 it is possible that 






















































































Figure 5 NK cell infusion in combination with metastasis- associated macrophage (MAM) depletion suppress metastatic tumor 
outgrowth. (A) A scheme of MAM depletion and NK cell infusion. C57BL/6 mice that received bone marrow transplantation 
(BMT) from Csf1r- cKO were intravenously injected with E0771- LG:Fluc cells after 6 weeks from BMT and treated with 
doxycycline (Dox) or vehicle (Veh) from day 4 after tumor injection. Cohorts of animals were intravenously injected with ex vivo 
cultured NK cells on day 7. (B and C) Representative bioluminescence images (B) and mean metastatic tumor loads (C) on 
days 4, 7, and 10 after tumor injection (n=8, Veh; n=8, Dox; n=7, Veh+NK; n=9, Dox+NK from two experiments). P values were 
calculated by Kruskal- Wallis test. All data show mean±SEM; *p<0.05; **p<0.01; ***p<0.001; ns, not significant. NK, natural killer.
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cells synergistically with mb- TGF-β during their differenti-
ation in the tumor microenvironment. The enhancement 
of NK cell recruitment into the parenchyma of metastatic 
lungs by MAM depletion also suggests the existence of 
additional mechanisms other than the mb- TGF-β depen-
dent NK cell suppression. In mouse models of pulmonary 
metastasis, NK cells introduced into the blood migrate 
evenly to the non- tumor area first, and then redistribute 
within the organ toward the metastatic tumor area.40 
Based on these results, it is possible that MAMs prevent the 
recruitment of circulating NK cells into the parenchyma 
of the metastatic lung, which subsequently reduces their 
accumulation within metastatic tumors. Our data suggest 
that MAMs also prevent differentiation of NK cells within 
the metastatic site. Although NK cells develop in the bone 
marrow and exit as mature cells, peripheral NK cell popu-
lations can also originate from site- specific immature NK 
cells.41 Although maturation status or origin of NK cells 
in human cancer is still unclear, a mouse study has shown 
that NK cells in primary mammary tumors express lower 
levels of CD27 compared with NK cells in the spleen,42 
suggesting the accumulation of immature NK cells in the 
tumor microenvironment. Since CD27low NK cells demon-
strate lower cytotoxicity against target cells compared with 
CD27high NK cells,43 these results suggest that prevention 
of NK cell maturation within the metastatic site may be 
another mechanism behind MAM mediated suppression 
of intrinsic NK cells in vivo.
This study also highlighted the importance of MAM 
targeting to enhance therapeutic efficacy of adop-
tively transferred NK cells. On the other hand, several 
studies have shown that MDSCs can suppress NK cell 
functions and are thus important targets to improve 
NK cell- based immunotherapies.44 MDSCs include two 
major subsets called monocytic (M-) and polymorpho-
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Figure 6 Transforming growth factor β (TGF-β) receptor antagonist enhances efficacy of NK cell infusion in suppressing 
metastatic tumor expansion. (A) A scheme of treatments. Tumor injected C57BL/6 or Csf1r- cKO mice were treated with 
doxycycline (Dox) from day 4 to day 14 after tumor injection and injected with TGF-β receptor antagonist (LY364947) or vehicle 
(Veh) every 2 days from day 4. Cohorts of animals were intravenously injected with ex vivo cultured NK cells on day 7 and day 
10. (B) Mean metastatic tumor loads in C57BL/6 mice on days 4, 7, 10, and 14 after tumor injection (n=5 in each group from 
two experiments). (C) Mean metastatic tumor loads in C57BL/6 mice on days 4, 7, 10, and 14 after tumor injection (n=6, vehicle; 
n=5, Veh+NK; n=5, LY+NK from two experiments). (D) Mean metastatic tumor loads in Csf1r- cKO mice on days 4, 7, 10, and 14 
after tumor injection (n=6, vehicle; n=5, Veh+NK; n=5, LY+NK from two experiments). P values were calculated by Kruskal- Wallis 
test. All data show mean±SEM; *p<0.05; ns, not significant. NK, natural killer.
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as CD11b+Ly6ChighLy6G− and CD11b+Ly6ClowLy6G+, 
respectively. However, most of the former studies used an 
anti- Gr-1 antibody that recognizes both Ly6C and Ly6G 
to identify MDSCs. Since PMN- MDSC but not M- MDSC 
subset inhibits the activation of NK cells in an in vitro 
model of vaccinia virus infection,45 it is possible that PMN- 
MDSCs rather than M- MDSCs play major roles in NK cell 
suppression in the particular tumor microenvironment. 
In line with this notion, blockade of PMN- MDSC recruit-
ment enhances therapeutic efficacy of transferred NK 
cells in a mouse model of oral cancer.46 However, deple-
tion of Ly6G+ cells did not alter the number of metastatic 
foci developed by E0771- LG cells in the lung,11suggesting 
minor contribution of PMN- MDSCs in metastatic forma-
tion in our model. These results emphasize the impor-
tance of the selection of target cell types appropriate to 
each cancer type in order to design an NK cell infusion 
therapy in combination with suppressor cell targeting.
In our experimental metastasis model, intravenously 
transplanted E0771- LG cells extravasate and colonize 
in the lung by day 4 after tumor injection, form small 
metastatic foci by day 7, and develop into lethal macro- 
metastatic lesions by day 14.11 15 Here, we have shown that 
NK cell infusion at day 7 reduces metastatic tumor growth 
by day 10 after tumor injection when macrophages are 
depleted or TGF-β signaling is blocked from day 4. These 
results indicate that NK cell infusion combined with 
MAM targeting can suppress expansion of metastatic 
tumor cells that have disseminated into the metastatic 
site and established small metastasis foci. In this model, 
however, the development of macro- metastatic lesions by 
day 14 was not suppressed by NK cell infusion combined 
with the TGF-β receptor antagonist, which suggests the 
involvement of other suppressive mechanisms in the 
later stage of metastatic tumor expansion. It has been 
reported that several cytokines such as IL-6, G- CSF, and 
activin- A can attenuate NK cell functions in vitro.46–48 It is 
possible that these cytokines are upregulated in macro- 
metastatic lesions and can also contribute to the reduced 
efficacy of infused NK cells. On the other hand, it is 
worth noting that the number of NK cells infused in this 
study (1×106) was much lower than that used in previous 
studies (5–10×106).49–52 It has been reported that NK cells 
in C57BL/6 mice can inhibit subcutaneous tumor growth 
when 1×103 of cancer cells are inoculated but fail to 
suppress tumor development initiated by 1×105 of cancer 
cells,53 suggesting the requirement for a certain number 
of NK cells to eliminate a large amount of cancer cells. It 
is therefore possible that efficient delivery of increased 
numbers of infused NK cells in addition to MAM targeting 
is necessary to suppress the outgrowth of established 
tumor lesions especially at later stage of metastasis.
In summary, this study indicates that MAMs are critical 
NK cell suppressors in metastatic tumors and provides a 
proof of concept that MAM targeting can improve the 
efficacy of NK cells. Further investigation of the mecha-
nism behind MAM- mediated NK cell suppression, along 
with definition of efficient NK cell delivery methods, will 
lead to the improvement of therapeutic efficacy of NK 
cell- infusion therapy for metastatic breast cancer.
Author affiliations
1MRC Centre for Reproductive Health, Queen’s Medical Research Institute, The 
University of Edinburgh, Edinburgh, UK
2Cancer Research UK Beatson Institute, Glasgow, UK
3Cancer Research UK Edinburgh Centre, MRC Institute of Genetics & Molecular 
Medicine, The University of Edinburgh, Edinburgh, UK
4Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
5Royal (Dick) School of Veterinary Studies and Roslin Institute, The University of 
Edinburgh, Edinburgh, UK
Acknowledgements The authors thank Dr Mihich for providing E0771 cells, Dr 
Webb for maintenance of mouse colonies, Dr Winchester for critique of the article, 
and Dr Pollard for scientific advice. Flow cytometry data were generated with 
support from the QMRI Flow Cytometry and Cell Sorting Facility, The University 
of Edinburgh. Histological data were generated with support from the Histology 
Facility, CRUK Beatson Institute.
Contributors DB and TK designed and carried out experiments and wrote the 
manuscript. DB, DD- S, TK, and NC established and performed the in vitro NK 
cell cytotoxicity assay. CN and LC generated histological data. DS carried out 
computational analyses of histological data.
Funding This study was funded by a Wellcome Trust Seed Award in Science 
(109657/ Z/15/Z) and a Medical Research Council (MRC) Career Development 
Award (MR/S006982/1) to TK. LMC laboratory is supported by Cancer Research UK 
(A17196 and A23983). NC laboratory is supported by Cancer Research UK funding 
(C42454/A28596 and C42454/A24892). The MRC Centre for Reproductive Health 
at the University of Edinburgh receives a core funding support from MRC (MR/
N022556/1).
Competing interests No, there are no competing interests.
Patient consent for publication Not required.
Ethics approval All animal experiments were performed in accordance with the 
Animals (Scientific Procedures) Act 1986, the EU Directive 2010/63, and under 
licensed permission from the UK Home Office (P526C60B3) and local ethics 
committee (BVS, University of Edinburgh).
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data sharing not applicable as no datasets generated 
and/or analyzed for this study. Data are available upon reasonable request. All 
data relevant to the study are included in the article or uploaded as supplementary 
information.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Demi Brownlie http:// orcid. org/ 0000- 0001- 5932- 6425
Takanori Kitamura http:// orcid. org/ 0000- 0003- 2032- 3918
REFERENCES
 1 Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA 
Cancer J Clin 2011;61:69–90.
 on O












12 Brownlie D, et al. J Immunother Cancer 2021;9:e001740. doi:10.1136/jitc-2020-001740
Open access 
 2 Dawood S, Broglio K, Ensor J, et al. Survival differences among 
women with de novo stage IV and relapsed breast cancer. Ann Oncol 
2010;21:2169–74.
 3 Steeg PS. Targeting metastasis. Nat Rev Cancer 2016;16:201–18.
 4 Kaneko K, Ishigami S, Kijima Y, et al. Clinical implication of HLA class 
I expression in breast cancer. BMC Cancer 2011;11:454.
 5 Homet Moreno B, Ribas A. Anti- programmed cell death protein-1/
ligand-1 therapy in different cancers. Br J Cancer 2015;112:1421–7.
 6 Cheng M, Chen Y, Xiao W, et al. Nk cell- based immunotherapy for 
malignant diseases. Cell Mol Immunol 2013;10:230–52.
 7 Ljunggren HG, Kärre K. In search of the 'missing self': MHC 
molecules and NK cell recognition. Immunol Today 1990;11:237–44.
 8 Dahlberg CIM, Sarhan D, Chrobok M, et al. Natural killer cell- based 
therapies targeting cancer: possible strategies to gain and sustain 
anti- tumor activity. Front Immunol 2015;6:605.
 9 Vitale M, Cantoni C, Pietra G, et al. Effect of tumor cells and 
tumor microenvironment on NK- cell function. Eur J Immunol 
2014;44:1582–92.
 10 Lin EY, Li J- F, Gnatovskiy L, et al. Macrophages regulate the 
angiogenic switch in a mouse model of breast cancer. Cancer Res 
2006;66:11238–46.
 11 Kitamura T, Qian B- Z, Soong D, et al. CCL2- Induced chemokine 
cascade promotes breast cancer metastasis by enhancing 
retention of metastasis- associated macrophages. J Exp Med 
2015;212:1043–59.
 12 Ewens A, Mihich E, Ehrke MJ. Distant metastasis from 
subcutaneously grown E0771 medullary breast adenocarcinoma. 
Anticancer Res 2005;25:3905–16.
 13 Kitamura T, Doughty- Shenton D, Pollard JW, et al. Real time 
detection of in vitro tumor cell apoptosis induced by CD8+ T cells 
to study immune suppressive functions of tumor- infiltrating myeloid 
cells. J Vis Exp 2019;143. doi:10.3791/58841. [Epub ahead of print: 
29 01 2019].
 14 Güç E, Brownlie D, Rodriguez- Tirado C, et al. Generation of 
mouse bone marrow- derived macrophages using tumor coculture 
assays to mimic the tumor microenvironment. Methods Enzymol 
2020;632:91–111.
 15 Kitamura T, Doughty- Shenton D, Cassetta L, et al. Monocytes 
differentiate to immune suppressive precursors of metastasis- 
associated macrophages in mouse models of metastatic breast 
cancer. Front Immunol 2017;8:2004.
 16 Smyth MJ, Teng MWL, Swann J, et al. CD4+CD25+ T regulatory cells 
suppress NK cell- mediated immunotherapy of cancer. J Immunol 
2006;176:1582–7.
 17 Mabbott NA, Kenneth Baillie J, Hume DA, et al. Meta- analysis of 
lineage- specific gene expression signatures in mouse leukocyte 
populations. Immunobiology 2010;215:724–36.
 18 Lacey DC, Achuthan A, Fleetwood AJ, et al. Defining GM- CSF- and 
macrophage- CSF- dependent macrophage responses by in vitro 
models. J Immunol 2012;188:5752–65.
 19 Qian B, Deng Y, Im JH, et al. A distinct macrophage population 
mediates metastatic breast cancer cell extravasation, establishment 
and growth. PLoS One 2009;4:e6562.
 20 Pegram HJ, Andrews DM, Smyth MJ, et al. Activating and inhibitory 
receptors of natural killer cells. Immunol Cell Biol 2011;89:216–24.
 21 Ghiringhelli F, Ménard C, Terme M, et al. CD4+CD25+ regulatory 
T cells inhibit natural killer cell functions in a transforming growth 
factor- beta- dependent manner. J Exp Med 2005;202:1075–85.
 22 Li H, Han Y, Guo Q, et al. Cancer- expanded myeloid- derived 
suppressor cells induce anergy of NK cells through membrane- 
bound TGF- beta 1. J Immunol 2009;182:240–9.
 23 Clausen J, Vergeiner B, Enk M, et al. Functional significance of the 
activation- associated receptors CD25 and CD69 on human NK- cells 
and NK- like T- cells. Immunobiology 2003;207:85–93.
 24 Dons'koi BV, Chernyshov VP, Osypchuk DV. Measurement of 
NK activity in whole blood by the CD69 up- regulation after 
co- incubation with K562, comparison with NK cytotoxicity 
assays and CD107a degranulation assay. J Immunol Methods 
2011;372:187–95.
 25 Sojka DK, Plougastel- Douglas B, Yang L, et al. Tissue- resident 
natural killer (NK) cells are cell lineages distinct from thymic and 
conventional splenic NK cells. Elife 2014;3:e01659.
 26 Cong J, Wei H. Natural killer cells in the lungs. Front Immunol 
2019;10:1416.
 27 Paul S, Lal G. The molecular mechanism of natural killer cells 
function and its importance in cancer immunotherapy. Front Immunol 
2017;8:1124.
 28 Chiossone L, Chaix J, Fuseri N, et al. Maturation of mouse NK cells 
is a 4- stage developmental program. Blood 2009;113:5488–96.
 29 Kitamura T, Kato Y, Brownlie D, et al. Mammary tumor cells with high 
metastatic potential are hypersensitive to macrophage- derived HGF. 
Cancer Immunol Res 2019;7:2052–64.
 30 Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in 
cancer immunotherapy. Nat Immunol 2016;17:1025–36.
 31 Srivastava MK, Zhu L, Harris- White M, et al. Myeloid suppressor 
cell depletion augments antitumor activity in lung cancer. PLoS One 
2012;7:e40677.
 32 Chen Q, Zhang XH- F, Massagué J. Macrophage binding to receptor 
VCAM-1 transmits survival signals in breast cancer cells that invade 
the lungs. Cancer Cell 2011;20:538–49.
 33 Kitamura T, Qian B- Z, Pollard JW. Immune cell promotion of 
metastasis. Nat Rev Immunol 2015;15:73–86.
 34 Mantovani A, Marchesi F, Malesci A, et al. Tumour- associated 
macrophages as treatment targets in oncology. Nat Rev Clin Oncol 
2017;14:399–416.
 35 Michel T, Poli A, Domingues O, et al. Mouse lung and spleen natural 
killer cells have phenotypic and functional differences, in part 
influenced by macrophages. PLoS One 2012;7:e51230.
 36 Yan J, Li X- Y, Roman Aguilera A, et al. Control of metastases via 
myeloid CD39 and NK cell effector function. Cancer Immunol Res 
2020;8:356–67.
 37 Krneta T, Gillgrass A, Poznanski S, et al. M2- polarized and tumor- 
associated macrophages alter NK cell phenotype and function in a 
contact- dependent manner. J Leukoc Biol 2017;101:285–95.
 38 Lee J- C, Lee K- M, Kim D- W, et al. Elevated TGF- beta1 secretion and 
down- modulation of NKG2D underlies impaired NK cytotoxicity in 
cancer patients. J Immunol 2004;172:7335–40.
 39 Gao Y, Souza- Fonseca- Guimaraes F, Bald T, et al. Tumor 
immunoevasion by the conversion of effector NK cells into type 1 
innate lymphoid cells. Nat Immunol 2017;18:1004–15.
 40 Basse P, Herberman RB, Nannmark U, et al. Accumulation of 
adoptively transferred adherent, lymphokine- activated killer cells in 
murine metastases. J Exp Med 1991;174:479–88.
 41 Pinhas N, Sternberg- Simon M, Chiossone L, et al. Murine peripheral 
NK- cell populations originate from site- specific immature NK 
cells more than from BM- derived NK cells. Eur J Immunol 
2016;46:1258–70.
 42 Krneta T, Gillgrass A, Chew M, et al. The breast tumor 
microenvironment alters the phenotype and function of natural killer 
cells. Cell Mol Immunol 2016;13:628–39.
 43 Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two 
subsets with distinct responsiveness and migratory capacity. J 
Immunol 2006;176:1517–24.
 44 Bruno A, Mortara L, Baci D, et al. Myeloid derived suppressor cells 
interactions with natural killer cells and pro- angiogenic activities: 
roles in tumor progression. Front Immunol 2019;10:771.
 45 Fortin C, Huang X, Yang Y. NK cell response to vaccinia virus 
is regulated by myeloid- derived suppressor cells. J Immunol 
2012;189:1843–9.
 46 Robson NC, Wei H, McAlpine T, et al. Activin- A attenuates several 
human natural killer cell functions. Blood 2009;113:3218–25.
 47 Schlahsa L, Jaimes Y, Blasczyk R, et al. Granulocyte- colony- 
stimulatory factor: a strong inhibitor of natural killer cell function. 
Transfusion 2011;51:293–305.
 48 Xu Y, Sun J, Sheard MA, et al. Lenalidomide overcomes suppression 
of human natural killer cell anti- tumor functions by neuroblastoma 
microenvironment- associated IL-6 and TGFβ1. Cancer Immunol 
Immunother 2013;62:1637–48.
 49 Ng YY, Tay JCK, Wang S. CXCR1 expression to improve anti- cancer 
efficacy of intravenously injected CAR- NK cells in mice with 
peritoneal xenografts. Mol Ther Oncolytics 2020;16:75–85.
 50 Lee J, Kang TH, Yoo W, et al. An antibody designed to improve 
adoptive NK- cell therapy inhibits pancreatic cancer progression in a 
murine model. Cancer Immunol Res 2019;7:219–29.
 51 Bonanni V, Antonangeli F, Santoni A, et al. Targeting of CXCR3 
improves anti- myeloma efficacy of adoptively transferred activated 
natural killer cells. J Immunother Cancer 2019;7:290.
 52 Greene S, Robbins Y, Mydlarz WK, et al. Inhibition of MDSC 
trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK- cell 
immunotherapy in head and neck cancer models. Clin Cancer Res 
2020;26:1420–31.
 53 Kim S, Iizuka K, Aguila HL, et al. In vivo natural killer cell activities 
revealed by natural killer cell- deficient mice. Proc Natl Acad Sci U S 
A 2000;97:2731–6.
 on O












BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer
 doi: 10.1136/jitc-2020-001740:e001740. 9 2021;J Immunother Cancer, et al. Brownlie D
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer
 doi: 10.1136/jitc-2020-001740:e001740. 9 2021;J Immunother Cancer, et al. Brownlie D
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) J Immunother Cancer
 doi: 10.1136/jitc-2020-001740:e001740. 9 2021;J Immunother Cancer, et al. Brownlie D
Supplementary Figure 4. Effects of macrophage depletion on the phenotype of NK
cells. Percentage of NK cells expressing CD49a (a marker of tissue-resident NK cell; left) or
CD49b (a mature marker of NK cells; right) in the tumor-bearing lung (n = 6 in each group
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